Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A geometric criterion links HIV-1 capsid topography to its biophysical properties and function.

Nature communications·2026
Same author

Rule-Based Ion Prediction with Orthogonal Constraints Reveals Bacterial Phospholipid Remodeling Signatures.

Antibiotics (Basel, Switzerland)·2026
Same author

Wearable In-Ear EEG: PEDOT-Leather Sensors for Comfortable Sleep Monitoring and Auditory Intervention.

ACS applied materials & interfaces·2026
Same author

Simultaneous measurement of large dynamic range transmitted wavefront and full-aperture diopter distribution for progressive addition lenses based on optical deflectometry.

Optics express·2026
Same author

Liquid-liquid phase separation of CBX2 regulates lipid raft-mediated extracellular vesicle biogenesis to facilitate ovarian carcinoma metastasis.

NPJ precision oncology·2026
Same author

A geometric criterion links HIV-1 capsid topography to its biophysical properties and function.

bioRxiv : the preprint server for biology·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same journal

Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same journal

Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

Seminars in thrombosis and hemostasis·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Therapeutic complement inhibition: new developments.

Woodruff Emlen1, Wenhan Li, Michael Kirschfink

  • 1Taligen Therapeutics, Cambridge, Massachusetts, USA.

Seminars in Thrombosis and Hemostasis
|September 25, 2010
PubMed
Summary
This summary is machine-generated.

Complement system activation drives inflammatory diseases. Therapies targeting complement components, like C5 and C1 inhibitor, show promise for treating conditions such as paroxysmal nocturnal hemoglobinuria and hereditary angioedema.

More Related Videos

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Area of Science:

  • Immunology
  • Pathophysiology
  • Pharmacology

Background:

  • The complement system plays a critical role in the pathogenesis of numerous acute and chronic inflammatory diseases.
  • Dysregulation of complement activation contributes to disease progression and severity.
  • Existing therapeutic strategies aim to modulate complement activity.

Purpose of the Study:

  • To review current therapeutic strategies for inhibiting the complement system.
  • To highlight the recent resurgence of interest in complement therapeutics.
  • To discuss the potential of complement inhibition in treating inflammatory diseases.

Main Methods:

  • Review of existing literature on complement inhibitors.
  • Analysis of approved complement-targeting therapies.
  • Discussion of therapeutic targets within the complement cascade.

Main Results:

  • Several strategies exist to inhibit complement, including replacement of inhibitors, antibody blockade of key proteins (e.g., C5), and receptor blockade (e.g., C5aR).
  • Recent approvals of anti-C5 for paroxysmal nocturnal hemoglobinuria and C1 inhibitor for hereditary angioedema demonstrate therapeutic success.
  • These approvals have renewed interest in developing complement-based treatments.

Conclusions:

  • Complement therapeutics offer a promising avenue for managing inflammatory diseases.
  • Targeting specific components of the complement cascade can effectively treat certain conditions.
  • Further research into complement inhibition holds significant potential for broader clinical applications.